Sanofi India Limited · NSE:SANOFI
Sanofi India — Investor Presentation (February 2024)
9 slides from Sanofi India's investor presentation, Feb 26, 2024
Slide 1: Outcome of Investor / Analysts Call letter to exchanges
26th February 2024 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor Dalal Street, Mumbai - 400 001 Plot No. C/1, G Block Scrip Code: 500674 Bandra-Kurla Complex, Bandra East Mumbai - 400 050 Symbol: SANOFI Sub: O
Slide 2: Investor Presentation
Investor Presentation February 26 , 2024
Slide 3: Disclaimer
Disclaimer This Release / Communication, except for the historical information, may contain statements, including the words or phrases such as expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should and similar expressions or
Slide 4: India for India | Pillars
Internal India for India | Pillars: Diabetes Consumer Healthcare E2E Innovation GTM Reduction of overlaps, Double down on winning Fully leverage global and Strengthen reach increase synergies and brand: Allegra local Innovation agility Expand spectrum Deployment of trade Deeper consumer offering Loc
Slide 5: SIL Innovation Pipeline
Internal SIL Inovation Pipeline: 2025 Oct 23 2024 Dec 23
Slide 6: Domestic Sales and Profit Before Tax Q4 & FY 22/23
Domestic Sales and Profit Before Tax Q4 & FY 22/23 Internal : Comp= Excluding NLEM price effect for Lantus PBT excluding divestment of Sofra ₹ in Cr. +4.6% +1.2% +10.6% Comp +5.4% Comp 502 525 2,108 2,134 +5.6% +12.8% 177 186 732 828 Q4 22 Q4 23 Q4 22 Q4 23 FY 22 FY 23 FY 22 FY 23 Domestic Retained
Slide 7: Consistent Increase in Operating profit both in terms of absolute value and % to sales
Consistent Increase in Operating profit both in terms of absolute value and % to sales Internal Excluding any exceptional items ₹ in Cr. Abs value Abs % 250 35% 32% 224 31% 206 28% 30% 28% 27% 27% 200 186 26% 177 182 174 170 24% 25% 154 150 20% 15% 100 10% 50 5% 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2022 202
Slide 8: Domestic Sales and Profit Before Tax Evolution
Internal Domestic Sales and Profit Before Tax Evolution: ₹ in Cr. CAGR 5.9 % CAGR 3.6 % 2,415 2,157 2,108 2,134 2,155 2,196 2,170 1,903 1,999 1,781 1,820 1,606 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 Domestic Sales Performance : Retained business Domestic Sales Performance : Publ
Slide 9: Thank You
sanofi Thank You